Alan Xiao

559 total citations
15 papers, 459 citations indexed

About

Alan Xiao is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Alan Xiao has authored 15 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pharmacology, 6 papers in Molecular Medicine and 5 papers in Epidemiology. Recurrent topics in Alan Xiao's work include Antibiotics Pharmacokinetics and Efficacy (6 papers), Antibiotic Resistance in Bacteria (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Alan Xiao is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (6 papers), Antibiotic Resistance in Bacteria (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Alan Xiao collaborates with scholars based in United States, United Kingdom and Belgium. Alan Xiao's co-authors include Jennifer A. Huntington, Benjamin Miller, David P. Nicolau, Amy T. Kan, Mason B. Tomson, Gopal Krishna, Musaed Al-Thubaiti, Gongmin Fu, Ellie Hershberger and Gurudatt Chandorkar and has published in prestigious journals such as Blood, Psychopharmacology and British Journal of Clinical Pharmacology.

In The Last Decade

Alan Xiao

15 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan Xiao United States 11 217 199 124 75 71 15 459
Di Zhao China 14 40 0.2× 5 0.0× 44 0.4× 7 0.1× 9 0.1× 38 591
Ruiqin Zhang China 13 23 0.1× 5 0.0× 29 0.2× 14 0.2× 5 0.1× 31 454
Srinivasa Rao Sirasanagandla India 12 26 0.1× 9 0.0× 30 0.2× 9 0.1× 96 509
Jorinde A. W. Polderman Netherlands 11 36 0.2× 5 0.0× 49 0.4× 12 0.2× 26 561
Hyun Ah Choi South Korea 12 7 0.0× 26 0.1× 18 0.1× 216 2.9× 22 427
Pakeezah Saadat Canada 6 114 0.5× 7 0.0× 9 0.1× 15 0.2× 8 384
Mehmet Ali Erdoğan Türkiye 13 23 0.1× 4 0.0× 20 0.2× 19 0.3× 2 0.0× 45 433
Pierre Decoodt Belgium 12 39 0.2× 3 0.0× 67 0.5× 8 0.1× 33 623
Kyung Wook Kim South Korea 9 12 0.1× 5 0.0× 37 0.3× 8 0.1× 36 293
Shaocheng Zhang China 11 34 0.2× 5 0.0× 27 0.2× 10 0.1× 32 456

Countries citing papers authored by Alan Xiao

Since Specialization
Citations

This map shows the geographic impact of Alan Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Xiao more than expected).

Fields of papers citing papers by Alan Xiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Xiao. The network helps show where Alan Xiao may publish in the future.

Co-authorship network of co-authors of Alan Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Xiao. A scholar is included among the top collaborators of Alan Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Xiao. Alan Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Xiao, Alan, Jennifer A. Huntington, Jianmin Long, & Luzelena Caro. (2018). Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection. International Journal of Antimicrobial Agents. 52(3). 324–330. 7 indexed citations
2.
Yu, Brian, Adedayo Adedoyin, Ellie Hershberger, et al.. (2018). Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo‐Controlled, Multiple‐Dose Study. Clinical Pharmacology in Drug Development. 7(4). 382–391. 14 indexed citations
3.
Xiao, Alan, Luzelena Caro, Myra W. Popejoy, Jennifer A. Huntington, & Ravina Kullar. (2016). PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease. Infectious Diseases and Therapy. 6(1). 137–148. 32 indexed citations
4.
Miller, Benjamin, et al.. (2016). Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects. Fundamental and Clinical Pharmacology. 30(6). 625–633. 11 indexed citations
5.
Xiao, Alan, Benjamin Miller, Jennifer A. Huntington, & David P. Nicolau. (2015). Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia. The Journal of Clinical Pharmacology. 56(1). 56–66. 123 indexed citations
6.
Chandorkar, Gurudatt, Alan Xiao, Samer Mouksassi, Ellie Hershberger, & Gopal Krishna. (2014). Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. The Journal of Clinical Pharmacology. 55(2). 230–239. 52 indexed citations
7.
Xiao, Alan, Gurudatt Chandorkar, Gopal Krishna, & Ellie Hershberger. (2014). 403Ceftolozane/Tazobactam (C/T) Dose Optimization in Patients with End Stage Renal Disease (ESRD) Requiring Hemodialysis (HD) Using Population Pharmacokinetics (pPK) and Monte Carlo Simulations (MCS). Open Forum Infectious Diseases. 1(suppl_1). S155–S156. 1 indexed citations
8.
Varnäs, Katarina, Svante Nyberg, Per Karlsson, et al.. (2011). Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C]AZ10419369. Psychopharmacology. 213(2-3). 533–545. 21 indexed citations
9.
Han, Tae Hyung, Rebecca Blanchard, John Palcza, et al.. (2010). Single‐ and Multiple‐Dose Pharmacokinetics and Tolerability of Telcagepant, an Oral Calcitonin Gene‐Related Peptide Receptor Antagonist, in Adults. The Journal of Clinical Pharmacology. 50(12). 1367–1376. 29 indexed citations
10.
Sinclair, Simon, Stefanie A. Kane, Bart Van der Schueren, et al.. (2009). Inhibition of capsaicin‐induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK‐0974). British Journal of Clinical Pharmacology. 69(1). 15–22. 70 indexed citations
11.
12.
13.
Giles, Francis J., Steven J. Freedman, Alan Xiao, et al.. (2006). MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.. Blood. 108(11). 1967–1967. 12 indexed citations
14.
Giles, Francis J., Jörge E. Cortes, Donald A. Bergstrom, et al.. (2006). MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML).. Blood. 108(11). 163–163. 12 indexed citations
15.
Kan, Amy T., Gongmin Fu, Mason B. Tomson, Musaed Al-Thubaiti, & Alan Xiao. (2004). Factors Affecting Scale Inhibitor Retention in Carbonate-Rich Formation During Squeeze Treatment. SPE Journal. 9(3). 280–289. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Di Zhao Breakdown of academic impact, for papers by Ruiqin Zhang Breakdown of academic impact, for papers by Srinivasa Rao Sirasanagandla Breakdown of academic impact, for papers by Jorinde A. W. Polderman Breakdown of academic impact, for papers by Hyun Ah Choi Breakdown of academic impact, for papers by Pakeezah Saadat Breakdown of academic impact, for papers by Mehmet Ali Erdoğan Breakdown of academic impact, for papers by Pierre Decoodt Breakdown of academic impact, for papers by Kyung Wook Kim Breakdown of academic impact, for papers by Shaocheng Zhang
Rankless by CCL
2026